<ripo class="btpidy"></ripo>

EVO视讯 EVO真人■

Be the most trusted biotech company

2025-11-03

Henlius Shines at CPHI 2025: Accelerating Global Access to China’s Biopharma Innovations
2025-10-23

On Site at JSCO | Henlius Advances Treatment Innovations in High-Incidence Cancers Across Asia
2025-10-22

Henlius Completes Patient Enrolment in the U.S. Bridging Study of Serplulimab in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2025-10-21

mOS in nsqNSCLC Exceeds Two Years! Henlius Announces Latest Results for Serplulimab at ESMO 2025
2025-10-20

Henlius Receives Orphan Drug Designation for PD-L1 ADC HLX43 in the U.S. for Thymic Epithelial Tumors
2025-10-15

Next-Gen Recombinant Human Hyaluronidase Debut — Meet Henlius at CPHI Worldwide 2025
2025-10-09

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
2025-09-30

U.S. FDA Clearance of IND for Ipilimumab Biosimilar HLX13
2025-09-30

Henlius Receives the NMPA IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-EGFR mAb HLX07